Synterica makes rationally engineered biologics for clinical use. The engineered biologics are proteins that contain a framework derived from robust antibodies found in camelids (camels, alpacas etc.). Variable sequences are placed between framework sequences to make engineered biologics. The process starts with a DNA library having a large binding repertoire. A selection process is then used to identify proteins with desired properties within that library. Targets are chosen based on selected diseases of interest.
Pre-clinical development is focused on two categories of diseases: infectious diseases and other medical conditions.
Infectious disease targets:
Synterica's products are in development and are not FDA approved therapeutics.
Copyright © 2020 Synterica - All Rights Reserved.